U.S. markets closed

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.2000+0.1400 (+13.21%)
At close: 3:59PM EDT

CytRx Corporation

11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
310 826 5648

Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven A. KriegsmanChairman & CEO1.01MN/A1942
Mr. John Y. CalozCFO, Treasurer & Sr. VP500kN/A1952
Molly Carey PoarchGlobal & U.S. Head of Corp. CommunicationsN/AN/AN/A
Ms. Molly PainterPres of USA and Head of Launch & Commercial OperationsN/AN/AN/A
Terri StevensChief Bus. OfficerN/AN/AN/A
Dr. Felix Kratz Ph.D.Sr. VP, Drug Devel.N/AN/A1963
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Corporate Governance

CytRx Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.